inventive Treatments to Successfully Target Malignant Pleural Mesothe…

Malignant Pleural Mesothelioma (MPM) is the most shared kind of mesothelioma with past asbestos exposure representing the major risk factor. While the search for new therapies that target the genes and processes driving MPM has been slow, two new approaches, which are closest obtainable to you, are showing meaningful improvements over standard treatment in clinical trials.

Before we discuss these enhanced treatment options, we must first briefly analyze two meaningful aspects of MPM progression: Angiogenesis and Epigenetic Regulation.

Angiogenesis:

Youve likely heard of Angiogenesis. It is the physiological course of action that tumors use to recruit new blood vessels in order to sustain their constant growth. They do this by manipulating the over-expression of genes that begin and direct the growth of new, leaky blood vessels from existing ones. This new supply of blood not only allows the tumor to grow, but also provides a mechanism for the tumor cells to metastasize (travel by the body).

the time of action of angiogenesis is governed by its own rare combination of genes, separate from those involved in the normal formation of new blood vessels (a course of action known as vasculogenesis). This, it turns out, provides us with an opportunity for successful treatment by the targeting of these rare gene combinations.

One of the most specific and basic regulators of angiogenesis is the family of vascular endothelial growth factors (VEGFs), which control endothelial proliferation (the formation of new blood vessels), blood canal permeability, and survival.In MPM,over-expression of VEGF is shared and correlates with lower remission rates and reduced overall patient survival. Clearly, effectively targeting VEGFs would consequence in limiting the blood supply to tumors consequently successfully prohibiting their growth. And thats just what we are seeing in current clinical trials. (More on that in a bit.)

Epigenetic Regulation:

A meaningful development in MPM treatment involves studies that focus on manipulating the processes of gene regulation, commonly referred to as epigenetic regulation. In MPM, tumor suppressor genes (the genes that, when functioning properly, naturally prohibit the growth of tumor cells) are silenced due to three meaningful forms of epigenetic regulation:

1. Removal of acetyl groups by histone deacetylases (HDACs);

2. Inhibition of histone acetyltransferases (HATs), which add acetyl groups; and

3. Addition of methyl groups by DNA methyltransferases (DNMTs).

In MPM, the over-expression of HDACs coupled with the inhibition of HATs is considered a meaningful course of action that leads to disease progression. The over-expression of DNMTs occurs in most cancers.

The assistance of targeting epigenetic processes is that they are reversible. Unlike a mutated gene which cannot be reactivated, it is possible to reactivate tumor suppressor genes that have been silenced by epigenetic processes. consequently, effective treatment must include some course of action whereby tumor suppressor genes are supported to continue their function and reactivated in situations where they have already been silenced.

To this end, there are numerous clinical trials currently exploring the use of rare combinations of drugs to hinder the silencing of tumor suppressor genes and to stop the flow of blood to tumors. Current clinical trials using HDAC and VEGF inhibitors are showing meaningful benefits in patient survival. For example, Vorinostat, an inhibitor of HDACs, has recently been shown to be advantageous for progressive mesothelioma patients whose cancer has progressed after standard chemotherapy.

The continued development and incorporation of these new drugs as part of standard treatment will undoubtedly be realized over the next few years. In the meantime there are some very simple and effective natural measures that you can take closest that will directly and powerfully influence the growth of cancer.

While clinical trials provide the basis for current molecular-targeted therapies, plant phytochemicals (also known as: Nutraceuticals) provide an exciting option as an additional method of gene regulation.

Science has identified the following nutraceuticals as having a meaningful effect in slowing the mechanisms involved in MPM progression. consequently it is imperative, as part of your treatment protocol, that you ensure these substances are a part of your daily diet in the appropriate combinations.

The following section is a list of nutraceuticals that have been shown to directly affect epigenetic regulation and angiogenisis in various cancers.

In order to hinder DNMTs to continue tumor suppressor gene function, we must consume the following foods:

Apigenin (Parsley, Thyme), Curcumin (Tumeric, Ginger, Mustard), EGCG (Green Tea, Nutmeg)

Genistein (Soy), Resveratrol (Red Wine, Grape Skins), Sulforaphane (Broccoli, Brussels Sprouts, Cabbages)

In order to hinder HDACs to continue tumor suppressor gene function, we must consume these foods:

Allyl Mercaptan(Garlic), Curcumin (Tumeric, Ginger, Mustard), Genistein (Soy) Sulforaphane (Broccoli, Brussels Sprouts, Cabbages)

In order to activate HATs to reactivate tumor suppressors, we must regularly consume these foods:

Curcumin (Tumeric, Ginger, Mustard), EGCG (Green Tea, Nutmeg), Genistein (Soy)

In order to hinder VEGFs to prevent further angiogenesis, we must ensure that these substances are a part of our daily diet:

Curcumin (Tumeric, Ginger, Mustard), EGCG (Green Tea, Nutmeg), 6-Gingerol (Ginger)

In Conclusion:

There are many molecular pathways and genes involved in MPM. Above we have explored just a few. However, including a daily diet of the nutraceuticals listed above will go a long way to enhance your statistical chances for remission and disease prevention, as these nutraceuticals are revealing themselves to be meaningful in the treatment and prevention of many forms of cancer.

Given the success of current clinical trials being conducted using molecular-targeted therapies this is also an important method to consider as an adjunct to standard treatment. Many clinical trials can be accessed from your home town by your current treatment specialist after a fleeting registration and testing course of action.

It is basic that you talk to your doctor before considering any changes to your diet as these nutraceuticals, while typically enhancing of any standard therapy, can interfere with prescription drugs.

If you would like more information on the use of nutraceuticals to enhance your life-expectancy or to have a personalized nutraceutical diet prepared for you, we welcome you to contact us @ [email protected] We are also happy to position to consult with your treatment team to proportion the most current information on enhanced treatment options and clinical trial access with them.

Patient Resources:

The Mesothelioma Center – The web based resource also provides free sustain sets for patients and families world-wide. For additional information please visit www.asbestos.com or call (800) 615-2270.

About the Author: